Horizon Therapeutics Public Limited Company NASDAQ:HZNP

Financial Health
0
1
2
3
4
5
6
7
8
9

Horizon Therapeutics Public Limited Company stock price monthly change

+0.68%
month

Horizon Therapeutics Public Limited Company stock price quarterly change

+14.66%
quarter

Horizon Therapeutics Public Limited Company stock price yearly change

+73.45%
year

Horizon Therapeutics Public Limited Company key metrics

Market Cap
N/A
Enterprise value
25.08B
P/E
49.34
EV/Sales
6.91
EV/EBITDA
25.06
Price/Sales
6.85
Price/Book
4.90
PEG ratio
-12.99
EPS
1.92
Revenue
3.64B
EBITDA
957.02M
Income
438.00M
Revenue Q/Q
7.82%
Revenue Y/Y
-4.42%
Profit margin
14.37%
Oper. margin
19.59%
Gross margin
74.64%
EBIT margin
19.59%
EBITDA margin
26.26%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Horizon Therapeutics Public Limited Company stock price history

Horizon Therapeutics Public Limited Company stock forecast

Horizon Therapeutics Public Limited Company financial statements

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Profit margin
Sep 2022 925.35M 135.83M 14.68%
Dec 2022 942.02M 120.40M 12.78%
Mar 2023 832.05M 54.68M 6.57%
Jun 2023 944.95M 127.07M 13.45%
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Earnings per share (EPS)
2023-03-01 1.09 1.21
2023-05-03 1.17 0.83
2023-08-08 1.12 1.2
2023-11-01 1.22 1.25
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Debt to assets
Sep 2022 9027862000 3.99B 44.24%
Dec 2022 9114616000 4.04B 44.35%
Mar 2023 8993450000 3.89B 43.34%
Jun 2023 9298741000 3.98B 42.89%
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Cash Flow
Sep 2022 366.46M -32.02M -94.37M
Dec 2022 426.39M -49.07M -160.96M
Mar 2023 86.32M -41.75M -88.12M
Jun 2023 161.46M -20.02M 9.03M

Horizon Therapeutics Public Limited Company alternative data

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Employee count
Aug 2023 2,145
Sep 2023 2,190
Oct 2023 2,190
Nov 2023 2,190
Dec 2023 2,190
Jan 2024 2,190
Feb 2024 2,190
Mar 2024 2,190
Apr 2024 2,190
May 2024 2,190
Jun 2024 2,190
Jul 2024 2,190

Horizon Therapeutics Public Limited Company other data

85.87% -0.73%
of HZNP is owned by hedge funds
202.60M -1.48M
shares is hold by hedge funds

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Insider trades (number of shares)
Period Buy Sel
Feb 2022 0 101313
Mar 2022 0 174933
Apr 2022 0 477366
May 2022 0 100000
Jun 2022 0 25762
Jul 2022 0 10939
Aug 2022 745 0
Dec 2022 0 58521
Jan 2023 0 75200
Transaction Date Insider Security Shares Price per share Total value Source
Option
MAHONY SUSAN director
Restricted Stock Units 3,913 N/A N/A
Option
DANIEL WILLIAM F director
Ordinary Shares 3,913 N/A N/A
Option
DANIEL WILLIAM F director
Restricted Stock Units 3,913 N/A N/A
Option
HIMAWAN JEFF director
Ordinary Shares 3,913 N/A N/A
Option
HIMAWAN JEFF director
Restricted Stock Units 3,913 N/A N/A
Option
GREY MICHAEL G director Ordinary Shares 3,913 N/A N/A
Option
GREY MICHAEL G director Restricted Stock Units 3,913 N/A N/A
Option
SHANNON JAMES SAMUEL director
Ordinary Shares 3,913 N/A N/A
Option
SHANNON JAMES SAMUEL director
Restricted Stock Units 3,913 N/A N/A
Option
MAHONY SUSAN director
Ordinary Shares 3,913 N/A N/A
Tuesday, 6 February 2024
Reuters
Thursday, 21 December 2023
Seeking Alpha
Friday, 13 October 2023
Seeking Alpha
Friday, 6 October 2023
Reuters
Wednesday, 6 September 2023
MarketBeat
Tuesday, 5 September 2023
CNBC
Business Wire
Friday, 1 September 2023
Fox Business
Invezz
Forbes
Barrons
CNBC Television
Market Watch
Reuters
CNBC
MarketBeat
Thursday, 31 August 2023
The Motley Fool
Monday, 28 August 2023
Forbes
Zacks Investment Research
Investopedia
Market Watch
Saturday, 26 August 2023
Reuters
Saturday, 12 August 2023
MarketBeat
Wednesday, 9 August 2023
Zacks Investment Research
Tuesday, 8 August 2023
Zacks Investment Research
Zacks Investment Research
Monday, 24 July 2023
Zacks Investment Research
Wednesday, 12 July 2023
Market Watch
Friday, 2 June 2023
Zacks Investment Research
Monday, 29 May 2023
Seeking Alpha
  • When is Horizon Therapeutics Public Limited Company's next earnings date?

    Unfortunately, Horizon Therapeutics Public Limited Company's (HZNP) next earnings date is currently unknown.

  • Does Horizon Therapeutics Public Limited Company pay dividends?

    No, Horizon Therapeutics Public Limited Company does not pay dividends.

  • What is Horizon Therapeutics Public Limited Company's stock symbol?

    Horizon Therapeutics Public Limited Company is traded on the NASDAQ under the ticker symbol "HZNP".

  • What is Horizon Therapeutics Public Limited Company's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - General industry.

  • How do i buy shares of Horizon Therapeutics Public Limited Company?

    Shares of Horizon Therapeutics Public Limited Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Horizon Therapeutics Public Limited Company's key executives?

    Horizon Therapeutics Public Limited Company's management team includes the following people:

    • Mr. Timothy P. Walbert Chairman, Pres & Chief Executive Officer(age: 58, pay: $5,480,000)
    • Mr. Paul W. Hoelscher Executive Vice President & Chief Financial Officer(age: 60, pay: $1,880,000)
    • Mr. Andy Pasternak Executive Vice President & Chief Strategy Officer(age: 54, pay: $1,790,000)
    • Mr. Barry J. Moze Executive Vice President & Chief Admin. Officer(age: 71, pay: $1,710,000)
    • Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. Executive Vice President & Chief Medical Officer(age: 70, pay: $1,550,000)
  • How many employees does Horizon Therapeutics Public Limited Company have?

    As Jul 2024, Horizon Therapeutics Public Limited Company employs 2,190 workers.

  • When Horizon Therapeutics Public Limited Company went public?

    Horizon Therapeutics Public Limited Company is publicly traded company for more then 14 years since IPO on 28 Jul 2011.

  • What is Horizon Therapeutics Public Limited Company's official website?

    The official website for Horizon Therapeutics Public Limited Company is horizontherapeutics.com.

  • How can i contact Horizon Therapeutics Public Limited Company?

    Horizon Therapeutics Public Limited Company can be reached via phone at +353 1 772 2100.

Horizon Therapeutics Public Limited Company company profile:

Horizon Therapeutics Public Limited Company

horizontherapeutics.com
Exchange:

NASDAQ

Full time employees:

2,190

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

70 St. Stephen’s Green
Dublin, 2

CIK: 0001492426
ISIN: IE00BQPVQZ61
CUSIP: G46188101